Oruka Therapeutics (NASDAQ:ORKA) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Oruka Therapeutics (NASDAQ:ORKA) issued its quarterly earnings data on Monday. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03), FiscalAI reports.

Oruka Therapeutics Price Performance

Shares of Oruka Therapeutics stock traded down $0.14 during trading on Tuesday, reaching $104.42. 66,358 shares of the stock traded hands, compared to its average volume of 1,073,650. The company has a market capitalization of $6.91 billion, a price-to-earnings ratio of -51.26 and a beta of -0.34. The business has a fifty day simple moving average of $88.48 and a two-hundred day simple moving average of $70.92. Oruka Therapeutics has a 52-week low of $25.23 and a 52-week high of $115.51.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ORKA shares. Guggenheim reissued a “buy” rating and issued a $200.00 price target on shares of Oruka Therapeutics in a report on Monday, October 26th. Piper Sandler reaffirmed an “overweight” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, October 13th. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Finally, Mizuho set a $120.00 price objective on shares of Oruka Therapeutics in a report on Thursday, September 3rd. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $133.00.

Insider Buying and Selling at Oruka Therapeutics

In other news, CEO Lawrence Klein sold 75,000 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the transaction, the chief executive officer directly owned 925,580 shares in the company, valued at approximately $84,996,011.40. This trade represents a 7.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00. Following the sale, the senior vice president directly owned 15,312 shares in the company, valued at approximately $1,633,177.92. The trade was a 39.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 179,950 shares of company stock worth $16,492,680 over the last quarter. Insiders own 23.49% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments.

The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.

Oruka was established around antibody programs developed by Paragon Therapeutics and became a publicly traded company in 2024 through a business combination with ARCA biopharma.